Role of DNA methylation and non‑coding RNAs expression in pathogenesis, detection, prognosis, and therapy‑resistant ovarian carcinoma (Review).

IF 3.5 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Molecular medicine reports Pub Date : 2025-06-01 Epub Date: 2025-04-04 DOI:10.3892/mmr.2025.13509

Victor M Del Castillo Falconi, Jenny A Godinez Rodriguez, Verónica Fragoso-Ontiveros, Laura Contreras-Espinosa, Abraham Pedroza-Torres, José Díaz-Chávez, Luis A Herrera

{"title":"Role of DNA methylation and non‑coding RNAs expression in pathogenesis, detection, prognosis, and therapy‑resistant ovarian carcinoma (Review).","authors":"Victor M Del Castillo Falconi, Jenny A Godinez Rodriguez, Verónica Fragoso-Ontiveros, Laura Contreras-Espinosa, Abraham Pedroza-Torres, José Díaz-Chávez, Luis A Herrera","doi":"10.3892/mmr.2025.13509","DOIUrl":null,"url":null,"abstract":"<p><p>Ovarian cancer is the deadliest gynecological cancer globally, with epithelial ovarian cancer (EOC) comprising up to 90% of cases. A molecular characterization linking the histological subtypes with tumor grade in EOC has been suggested. Variations in genetic biomarkers such as BRCA1/2, MSH2, MLH1/6, BRIP1, and RAD51C/D have been studied in EOC. In addition, molecular characteristics, including DNA methylation and RNA transcription, are being explored as potential new biomarkers for the diagnosis and prognosis of this type of neoplasia. The present review focused on the role of DNA methylation and non‑coding RNA expression in the development of ovarian carcinomas and their association with diagnosis, prognosis, and the resistance of cancer cells to radiotherapy and chemotherapy. The present review considered the transition from the DNA structure to the RNA expression in ovarian carcinoma.</p>","PeriodicalId":18818,"journal":{"name":"Molecular medicine reports","volume":"31 6","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11979574/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular medicine reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/mmr.2025.13509","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Ovarian cancer is the deadliest gynecological cancer globally, with epithelial ovarian cancer (EOC) comprising up to 90% of cases. A molecular characterization linking the histological subtypes with tumor grade in EOC has been suggested. Variations in genetic biomarkers such as BRCA1/2, MSH2, MLH1/6, BRIP1, and RAD51C/D have been studied in EOC. In addition, molecular characteristics, including DNA methylation and RNA transcription, are being explored as potential new biomarkers for the diagnosis and prognosis of this type of neoplasia. The present review focused on the role of DNA methylation and non‑coding RNA expression in the development of ovarian carcinomas and their association with diagnosis, prognosis, and the resistance of cancer cells to radiotherapy and chemotherapy. The present review considered the transition from the DNA structure to the RNA expression in ovarian carcinoma.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

DNA甲基化和非编码rna表达在卵巢癌发病、检测、预后和治疗抵抗中的作用（综述）。

卵巢癌是全球致死率最高的妇科癌症，其中上皮性卵巢癌（EOC）占90%。有研究表明，EOC 的组织学亚型与肿瘤分级之间存在分子特征。对 EOC 中 BRCA1/2、MSH2、MLH1/6、BRIP1 和 RAD51C/D 等遗传生物标志物的变异进行了研究。此外，包括 DNA 甲基化和 RNA 转录在内的分子特征也正在被探索作为诊断和预后这类肿瘤的潜在新生物标志物。本综述侧重于 DNA 甲基化和非编码 RNA 表达在卵巢癌发展中的作用，以及它们与诊断、预后和癌细胞对放疗和化疗的耐药性之间的关系。本综述考虑了卵巢癌中从 DNA 结构到 RNA 表达的转变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Molecular medicine reports 医学-病理学

CiteScore

7.60

自引率

0.00%

发文量

321

审稿时长

1.5 months

期刊介绍： Molecular Medicine Reports is a monthly, peer-reviewed journal available in print and online, that includes studies devoted to molecular medicine, underscoring aspects including pharmacology, pathology, genetics, neurosciences, infectious diseases, molecular cardiology and molecular surgery. In vitro and in vivo studies of experimental model systems pertaining to the mechanisms of a variety of diseases offer researchers the necessary tools and knowledge with which to aid the diagnosis and treatment of human diseases.